
Shandong Xinhua Pharmaceutical Company Limited
0719.HKHKSEHealthcareMedical - Pharmaceuticals
最新資料
HK$5.77
+HK$0.03 · +0.52%
0719.HK公司概覽
盤中時間採用HKT。市場資料可能有所延遲。
公司概況
公司網站Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
- 產業
- Medical - Pharmaceuticals
- 部門
- Healthcare
- 總部
- CN
- 執行長
- Wen Hui Xu
- 上市以來
- 2000年1月4日
- 僱員
- 7,240
市場位置
日內區間
目前HK$5.77,
52週區間
目前HK$5.77,
- 開盤價
- HK$5.74
- 前收盤價
- HK$5.74
- 成交量
- 15.2萬
- 0.1× 平均值
- 平均成交量
- 152.94萬
- 日均成交量
- 市值
- 86.93億 HKD
- 貝塔
- -0.03
- 市場參考 1
- 50天平均值
- HK$5.9673
- 低於平均水平-3.31%
- 200天平均值
- HK$6.4862
- 低於平均水平-11.04%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 39.97億 CNY
- 本益比(TTM)
- 35.95×
- 股價淨值比(TTM)
- 1.76×
- 股價營收比(TTM)
- 0.78×
- EV/EBITDA
- 4.04×
- 盈餘收益率
- 7.10%
- 自由現金流收益率
- 10.24%
- 股息率
- 1.11%
獲利能力和效率
- 毛利率
- 18.63%
- 營業利益率
- 3.99%
- 淨利潤率
- 2.99%
- 股東權益報酬率
- 5.56%
- 資產報酬率
- 3.15%
- 投入資本報酬率
- 4.03%
財務健康
- 負債權益比
- 0.36×
- 流動比率
- 1.43×
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(CNY) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 87.55億 CNY | 84.66億 CNY | 81.01億 CNY | 75.03億 CNY | 65.6億 CNY |
| 銷貨成本 | 71.1億 CNY | 64.25億 CNY | 57.79億 CNY | 54.66億 CNY | 47.86億 CNY |
| 毛利 | 16.45億 CNY | 20.42億 CNY | 23.21億 CNY | 20.37億 CNY | 17.74億 CNY |
| 研究與開發 | 4.4億 CNY | 4.13億 CNY | 4.19億 CNY | 3.46億 CNY | 3.41億 CNY |
| 銷售、一般及管理費用 | 3.41億 CNY | 6.08億 CNY | 12.98億 CNY | 8.15億 CNY | 6.89億 CNY |
| 營業費用 | 12.28億 CNY | 15.07億 CNY | 17.87億 CNY | 14.94億 CNY | 12.75億 CNY |
| 利息收入 | 748.65萬 CNY | 1112.55萬 CNY | 937.68萬 CNY | 1046.2萬 CNY | 877.63萬 CNY |
| 利息支出 | 4333.2萬 CNY | 3973.93萬 CNY | 4114.86萬 CNY | 4970.69萬 CNY | 5310.34萬 CNY |
| 折舊和攤銷 | 5.88億 CNY | 5.41億 CNY | 5.17億 CNY | 4.85億 CNY | 4.34億 CNY |
| 營業利益 | 3.64億 CNY | 5.34億 CNY | 5.35億 CNY | 4.77億 CNY | 4.26億 CNY |
| 淨利 | 2.9億 CNY | 4.7億 CNY | 4.97億 CNY | 4.11億 CNY | 3.49億 CNY |
公司資料更新於 2026年8月25日。
0719.HK同業公司
持有0719.HK的ETF
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P Emerging Markets Small Cap ETFEWX16.2萬0.02%6.88億 USD0.65%US$72.645+1.29%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM15.97萬0.00%93.99億 USD0.39%US$40.13+1.52%
Dimensional - Emerging Core Equity Market ETFDFAE13.77萬0.00%98.76億 USD0.29%US$39.625+1.52%
Dimensional World ex U.S. Core Equity 2 ETFDFAX10.2萬0.00%125.56億 USD0.28%US$38.27+0.82%
Dimensional - Emerging Markets Value ETFDFEV5.13萬0.00%20.91億 USD0.46%US$42.239+1.39%
State Street SPDR S&P Emerging Markets Small Cap ETFEWX- 市場價值
- 16.2萬
- 重量
- 0.02%
- AUM
- 6.88億 USD
- 費用率
- 0.65%
- 價格 / 1日
- US$72.645+1.29%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM- 市場價值
- 15.97萬
- 重量
- 0.00%
- AUM
- 93.99億 USD
- 費用率
- 0.39%
- 價格 / 1日
- US$40.13+1.52%
Dimensional - Emerging Core Equity Market ETFDFAE- 市場價值
- 13.77萬
- 重量
- 0.00%
- AUM
- 98.76億 USD
- 費用率
- 0.29%
- 價格 / 1日
- US$39.625+1.52%
Dimensional World ex U.S. Core Equity 2 ETFDFAX- 市場價值
- 10.2萬
- 重量
- 0.00%
- AUM
- 125.56億 USD
- 費用率
- 0.28%
- 價格 / 1日
- US$38.27+0.82%
Dimensional - Emerging Markets Value ETFDFEV- 市場價值
- 5.13萬
- 重量
- 0.00%
- AUM
- 20.91億 USD
- 費用率
- 0.46%
- 價格 / 1日
- US$42.239+1.39%
繼續GoAI的研究
在 GoAI 中研究0719.HKresearch.disclaimer





